Dupixent Lymphoma Lawsuit

Dupixent (dupilumab) has been linked in medical studies and FDA safety reviews to an increased risk of cutaneous T‑cell lymphoma (CTCL), including mycosis fungoides and Sézary syndrome, in some patients prescribed Dupixent for eczema, asthma, and other conditions.

Quick Facts About the Dupixent Lymphoma Lawsuit

If you or a loved one received Dupixent injections and were later diagnosed with a rare T‑cell lymphoma affecting the skin, you may be eligible to pursue compensation through a Dupixent CTCL lawsuit.

Key Medical Evidence: A 2024 population‑level study found that patients with atopic dermatitis treated with dupilumab had a 4.59‑times higher relative risk of developing cutaneous T‑cell lymphoma compared to similar patients never treated with Dupixent.
Cancer Types at Issue: Lawsuits focus on cutaneous T‑cell lymphomas, especially mycosis fungoides and Sézary syndrome, that were diagnosed or significantly worsened after starting Dupixent.
FDA Safety Signal: The FDA’s FAERS Potential Signals of Serious Risks report lists Dupixent (dupilumab) – Cutaneous T-cell lymphoma as a potential safety signal, stating it is evaluating whether regulatory action or label changes are needed.
Lawsuit Status (Feb. 2026): Dupixent lymphoma lawsuits are in the early stages; the first individual and wrongful death cases have been filed, no MDL has been formed yet, and no jury verdicts or global settlements have been reached.
Allegations Against Drugmakers: Plaintiffs allege that Sanofi and Regeneron failed to adequately warn doctors and patients about a potential link between Dupixent and CTCL, even as case reports, cohort studies, and FDA adverse‑event data suggested a cancer risk.

Dupixent Lymphoma CASE REVIEW

CALL NOW: 1-866-374-0338

Full Name*

Email*

Phone Number*

Please describe your situation *

Have you or your loved one experienced either of the following? (Select all that apply)

Used Dupixent (dupilumab) for at least 1-3 months

Diagnosed with cutaneous T‑cell lymphoma (CTCL), mycosis fungoides, or Sezary syndrome

I agree and acknowledge that by submitting this form, The Johnson Law Firm may contact me by phone call or text message regarding my inquiry. Message and data rates may apply. Message frequency will vary. I can reply STOP to opt out at any time or HELP for assistance. I also agree to the Terms of Use and Privacy Policy of The Johnson Law Firm. I understand that submission of this form does not create an attorney-client relationship, and that any information I provide will be used to evaluate my potential case. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

What is Cutaneous T‑Cell Lymphoma (CTCL) and How Is It Linked to Dupixent?

Dermatologist examining skin lesions on a patient's back during evaluation for cutaneous T-cell lymphoma (CTCL) after Dupixent use

Cutaneous T‑cell lymphoma (CTCL) is a rare type of non‑Hodgkin lymphoma in which cancerous T‑cells build up in the skin, causing patches, plaques, or tumors that can look very similar to eczema or psoriasis. The most common forms are mycosis fungoides and the more aggressive Sézary syndrome, which may eventually involve the blood and lymph nodes as well as the skin. Read more about CTCL on the American Academy of Dermatology

Because CTCL often develops slowly and mimics other skin conditions, it is frequently misdiagnosed for months or even years before a correct diagnosis is made through skin biopsies, blood tests, and specialist review by a dermatologist or oncologist. Treatment may include topical therapies, phototherapy, systemic medications, or chemotherapy and is often focused on controlling symptoms and slowing disease progression rather than curing the cancer outright.

Recent case reports and observational studies suggest that Dupixent (dupilumab) may unmask or accelerate CTCL in some patients who were originally treated for atopic dermatitis, leading to concerns that what appeared to be stubborn eczema was actually an underlying skin lymphoma. Dupixent lymphoma lawsuits are now investigating this potential connection and seeking accountability for patients who developed CTCL, mycosis fungoides, or Sezary syndrome after receiving the drug.

Do You Qualify for a Dupixent CTCL lawsuit?

Medical Criteria

You may have a case if you received a CTCL diagnosis while or after using Dupixent:

Received Dupixent (dupilumab) injections for at least 1-3 months for atopic dermatitis, asthma, chronic sinusitis with nasal polyps, or another approved condition.
Later diagnosed with cutaneous T‑cell lymphoma (CTCL) by a dermatologist or oncologist.
Diagnosed with a CTCL subtype such as mycosis fungoides or Sézary syndrome after starting Dupixent.
Experienced a persistent or worsening “eczema‑like” rash that did not improve on Dupixent and was eventually found to be CTCL on biopsy.
No prior history of lymphoma or leukemia before the first Dupixent dose.
Able to provide, or help us obtain, records confirming the timeline from first Dupixent injection to CTCL or mycosis fungoides diagnosis.

Preferred Documentation

After your diagnosis, gathering these documents strengthens your claim:

Dupixent prescription and injection records (pharmacy printouts, specialty‑pharmacy deliveries, clinic or infusion notes).
Dermatology and oncology records, including clinic notes, staging information, and treatment plans for CTCL, mycosis fungoides, or Sézary syndrome.
Dermatologist or oncologist consultation notes documenting CTCL evaluation, staging, or treatment planning.
Pathology and biopsy reports confirming cutaneous T‑cell lymphoma or suspicious T‑cell infiltrates.
Imaging and lab reports, such as PET/CT scans or blood tests used to evaluate spread beyond the skin.
Hospital and treatment billing statements showing dates of Dupixent therapy and cancer care.
A simple timeline of symptoms, Dupixent injections, and when CTCL or mycosis fungoides was first suspected or diagnosed.

Have you or a loved one been diagnosed with CTCL, mycosis fungoides, or Sezary syndrome after using Dupixent? Get a free case review →

Have You Experienced These Symptoms?

These symptoms may be associated with cutaneous T-cell lymphoma (CTCL) or mycosis fungoides – particularly in patients who are or were taking Dupixent. If you have not yet received a diagnosis, speaking with a medical professional may be an important next step.

Red, scaly, or “eczema‑like” patches that don’t improve with Dupixent

Thickened plaques or raised lesions on the skin

Itching or burning that persists or worsens over time

Skin tumors or nodules that appear on top of existing rashes

Swollen lymph nodes in the neck, armpits, or groin

Unexplained fatigue, fevers, or night sweats

Once you have a diagnosis, we’re here to review your legal options. Contact us for a free case evaluation.

Get a free case review →

ALERT: A persistent or worsening “eczema‑like” rash that doesn’t respond to Dupixent could be a sign of cutaneous T‑cell lymphoma or mycosis fungoides. Talk with your doctor about testing, then contact us to review your legal options.

Dupixent Lymphoma Lawsuit Timeline

From FDA approval through today’s litigation, here are key milestones in the Dupixent lymphoma lawsuit.

2017

2017 – FDA APPROVES DUPIXENT (DUPILUMAB)

The FDA approves Dupixent to treat adults with moderate‑to‑severe atopic dermatitis, later expanding the label to include asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and certain pediatric patients.

2018-2023

2018-2023 – CASE REPORTS LINK DUPILUMAB TO CTCL

Dermatologists publish case reports describing patients whose presumed eczema worsened on Dupixent and was later diagnosed as cutaneous T‑cell lymphoma, including mycosis fungoides and Sézary syndrome.

2024

2024 – STUDIES REPORT HIGHER CTCL RISK WITH DUPIXENT

A 2024 retrospective cohort study finds that atopic dermatitis patients treated with dupilumab have about a 4.59‑times higher relative risk of developing CTCL compared to similar patients who never received Dupixent, prompting growing concern among clinicians.

2025

2025 – FDA ADDS DUPIXENT-CTCL SAFETY SIGNAL

The FDA identified “Dupixent (dupilumab) – Cutaneous T-cell lymphoma” as a potential safety signal in its FAERS Potential Signals of Serious Risks report, confirming that regulators are actively evaluating whether label changes or other actions are warranted.

Late 2025

LATE 2025 – FIRST DUPIXENT LYMPHOMA LAWSUITS FILED

Patients and families file the first Dupixent lymphoma lawsuits, including a high‑profile wrongful death case alleging that Dupixent use for eczema preceded a fatal CTCL diagnosis.

2026

2026 AND BEYOND – DUPIXENT CTCL LITIGATION EXPANDS

As of early 2026, Dupixent lymphoma lawsuits are in the early stages in federal and state courts, with additional CTCL and mycosis fungoides cancer claims expected while the FDA’s safety review continues.

Harmed by Dupixent?

Get answers. Get help. Start your free Dupixent lymphoma case review.

Call Now!
1-866-374-0338

or

Get Started!
Request a callback online

With experienced mass tort attorneys and a dedicated team focused on complex litigation, The Johnson Law Firm stands up to large corporations on behalf of individuals and families. We are proud to represent clients across the U.S. in high-stakes cases involving serious harm from dangerous products.

Real Results From Real Clients

“My dad was quite happy with the job his lawyers at JLF did for him. JLF got the job done. He didn’t expect to get the amount of money that he did, and he was quite pleased.”
– Charles J.

Johnson Law Firm attorney reviewing a Dupixent lymphoma lawsuit case with a client during a free consultation

How a Dupixent Lymphoma Lawsuit Works

Dupixent (dupilumab) was approved in 2017 to treat chronic inflammatory conditions, but emerging research and case reports now suggest it may unmask or accelerate cutaneous T‑cell lymphoma (CTCL) in some patients. When a prescription drug is linked to a serious cancer risk and manufacturers fail to provide adequate warnings, patients and families can pursue compensation through a Dupixent lymphoma lawsuit.

Signal Detection: Case reports and systematic reviews began documenting patients whose “eczema” worsened on Dupixent and was later diagnosed as CTCL, including mycosis fungoides and Sézary syndrome.
Epidemiologic Evidence: A 2024 retrospective cohort study found that atopic dermatitis patients treated with dupilumab had a significantly increased relative risk – about 4.59‑fold – of developing cutaneous T‑cell lymphoma compared to similar patients who never received Dupixent.
Regulatory Review: In 2025, the FDA listed “Dupixent (dupilumab) – Cutaneous T‑cell lymphoma” as a potential safety signal and began evaluating whether additional warnings or label changes are needed.
Causation Proof: Dermatologists, oncologists, and hematopathologists review biopsy slides, medical histories, and published literature to help explain how blocking certain immune pathways with Dupixent may allow malignant T‑cells in the skin to grow unchecked in susceptible patients.
Compensation: A Dupixent cutaneous T‑cell lymphoma lawsuit may seek damages for cancer treatment costs, ongoing medical care, pain and suffering, loss of income, and, in wrongful death cases, losses suffered by surviving family members.
Liability Theories: Plaintiffs allege failure to warn, negligent pharmacovigilance, and defective design or marketing – arguing that Sanofi and Regeneron did not adequately disclose the potential CTCL risk or act quickly enough once red flags appeared.

Cases like this are pursued under dangerous prescription drugs, which holds drug manufacturers legally responsible when they fail to adequately warn patients and doctors about known or knowable risks associated with their products.

Results‑Driven Representation: If you have been diagnosed with CTCL or mycosis fungoides and were taking Dupixent, The Johnson Law Firm will review your medical records at no cost, work with medical experts to evaluate the connection, and pursue the maximum compensation available under the law.

How We Help Dupixent Lymphoma Victims

At The Johnson Law Firm, we take a strategic, compassionate approach to every Dupixent lymphoma lawsuit. Our goal is to uncover what happened, hold drug manufacturers accountable, and seek maximum compensation for patients and families facing cutaneous T‑cell lymphoma, mycosis fungoides, or Sézary syndrome after Dupixent use.

Our Process:

Medical & Pathology Record Review: We gather and review your Dupixent prescription history, dermatology notes, oncology records, and skin‑biopsy or pathology reports to confirm the CTCL diagnosis and timeline.
Expert Consultation Network: We work with dermatologists, hematologist‑oncologists, and dermatopathologists familiar with Dupixent‑related CTCL to help evaluate causation and support your claim.
Scientific & Regulatory Analysis: Our team analyzes published case reports, cohort studies, and FDA safety communications to show how medical evidence and adverse‑event data raised red flags about a possible Dupixent-CTCL connection.
Strategic Litigation Planning: We determine the best forum for your Dupixent lymphoma lawsuit – federal or state court – and tailor a strategy around your diagnosis, treatment course, and damages.
Contingency‑Fee Representation: You owe no attorney’s fees unless we recover money in your case; we advance litigation costs and are paid only if we obtain a settlement or verdict on your behalf.

You focus on your health and your family while we focus on building the strongest possible Dupixent lymphoma case and pursuing the full compensation the law allows.

Dupixent Lymphoma Lawsuit FAQs

A Dupixent lymphoma lawsuit is a legal claim filed by patients who used Dupixent (dupilumab) and were later diagnosed with cutaneous T‑cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome. These cases allege that the drug makers failed to adequately warn about a potential increased cancer risk and seek compensation for medical costs, lost income, and other losses tied to the CTCL diagnosis.

Case reports and observational studies have documented patients whose presumed eczema worsened on Dupixent and was later found to be CTCL, and at least one large study reported about a 4.59‑fold higher relative risk of CTCL in dupilumab‑treated atopic dermatitis patients compared with those never exposed to the drug. The FDA has flagged “Dupixent – cutaneous T‑cell lymphoma” as a potential safety signal and is reviewing whether label changes are needed.

Possible CTCL symptoms include persistent, “eczema‑like” patches or plaques that don’t respond to treatment, thickened or scaly areas of skin, new skin tumors or nodules, intense itching or burning, swollen lymph nodes, and systemic symptoms like fatigue, fevers, or night sweats. Anyone on Dupixent who notices these changes should speak with a dermatologist or oncologist and ask whether additional testing – such as skin biopsies or blood work – is appropriate.

You may qualify if you used Dupixent for an approved condition (often for at least 1-3 months) and were later diagnosed with CTCL or a CTCL subtype like mycosis fungoides or Sézary syndrome, with no history of lymphoma or leukemia before starting the drug. A law firm will also look at the timing of your Dupixent use, when your symptoms first appeared, and what pathology reports show about your cancer.

Helpful evidence can include Dupixent prescription and injection records, dermatology and oncology notes, pathology and biopsy reports confirming CTCL, imaging and lab results, and a timeline showing when you started Dupixent and when cancer was diagnosed. Insurance statements and hospital bills can also help document treatment costs and the financial impact of the disease.

As of early 2026, Dupixent lymphoma lawsuits are in the early stages and have not yet been consolidated into a formal multidistrict litigation (MDL), though centralized proceedings may develop if enough cases are filed. Individual cases are being brought in state and federal courts, and future filings could lead to a JPML order creating a Dupixent CTCL MDL similar to other drug mass torts.
The Johnson Law Firm has experience handling mass tort and dangerous drug claims in both individual and coordinated proceedings nationwide.

Most firms handling Dupixent lymphoma lawsuits work on a contingency fee basis, meaning you do not pay hourly rates or up‑front retainers and the firm only receives a fee if there is a settlement or verdict in your favor. The attorney’s fee is typically a percentage of the recovery plus reimbursed case expenses, as outlined in your written representation agreement.

While outcomes vary, a Dupixent CTCL lawsuit may seek damages for past and future medical treatment, prescription drugs, travel for care, lost wages or reduced earning capacity, pain and suffering, emotional distress, and loss of enjoyment of life. In wrongful death cases, families may also pursue funeral expenses and certain losses related to the death of a loved one, depending on state law.

Cutaneous T‑cell lymphoma is a rare non‑Hodgkin lymphoma where malignant T‑cells collect in the skin; mycosis fungoides is its most common form, and Sezary syndrome is a more aggressive variant that involves the blood and lymph nodes. These cancers can mimic eczema or psoriasis early on, which is why repeated biopsies and specialist evaluation are often needed for a correct diagnosis.

Cutaneous T‑cell lymphoma is a rare non‑Hodgkin lymphoma where malignant T‑cells collect in the skin; mycosis fungoides is its most common form, and Sézary syndrome is a more aggressive variant that involves the blood and lymph nodes. These cancers can mimic eczema or psoriasis early on, which is why repeated biopsies and specialist evaluation are often needed for a correct diagnosis.

Ready for your free Dupixent lymphoma case review?

If you were diagnosed with cutaneous T‑cell lymphoma, mycosis fungoides, or Sezary syndrome after using Dupixent, our attorneys will review your medical records and treatment history at no out‑of‑pocket cost to you.